A potent P2X1 receptor antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

NF449 (sodium salt)

Item No. 13324

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4,4',4'',4'''-[carbonylbis[imino-5,1,3-benzenetriylbis(carbonylimino)]]tetrakis-1,3-benzenedisulfonic acid, octasodium salt
CAS Number
627034-85-9
Molecular Formula
C41H24N6O29S8 • 8Na
Formula Weight
1505.1
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
PBS (pH 7.2): 10 mg/ml
λmax
277 nm
SMILES
O=C(NC1=CC(C(NC2=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C=C2)=O)=CC(C(NC3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C=C3)=O)=C1)NC4=CC(C(NC5=CC=C(S([O-])(=O)=O)C=C5S([O-])(=O)=O)=O)=CC(C(NC6=CC=C(S([O-])(=O)=O)C=C6S([O-])(=O)=O)=O)=C4.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
InChi Code
InChI=1S/C41H32N6O29S8.8Na/c48-37(44-29-5-1-25(77(53,54)55)15-33(29)81(65,66)67)19-9-20(38(49)45-30-6-2-26(78(56,57)58)16-34(30)82(68,69)70)12-23(11-19)42-41(52)43-24-13-21(39(50)46-31-7-3-27(79(59,60)61)17-35(31)83(71,72)73)10-22(14-24)40(51)47-32-8-4-28(80(62,63)64)18-36(32)84(74,75)76;;;;;;;;/h1-18H,(H,44,48)(H,45,49)(H,46,50)(H,47,51)(H2,42,43,52)(H,53,54,55)(H,56,57,58)(H,59,60,61)(H,62,63,64)(H,65,66,67)(H,68,69,70)(H,71,72,73)(H,74,75,76);;;;;;;;/q;8*+1/p-8
InChi Key
KCBZSNWCUJBMHF-UHFFFAOYSA-F
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $41

    Add

    5 mg

    $99

    Add

    10 mg

    $178

    Add

    50 mg

    $775

    Add
    Product Description

    NF449 is an analog of suramin that selectively inhibits P2X1 purinergic receptors (pIC50 = 6.3) with a potency 19-fold greater than at P2X3, P2Y1, P2Y2, or P2Y11.1,2 Through selective inhibition of the P2X1 receptor, 10 mg/kg NF449 has been used to decrease intravascular platelet aggregation in a mouse model of systemic thromboembolism.3 NF449 has also demonstrated selective antagonism of the Gsα-subunit G protein, which suppresses the association rate of GTPγS binding to Gsα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks G protein coupling to certain GPCRs.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kassack, M.U., Braun, K., Ganso, M., et al. Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur. J. Med. Chem. 39(4), 345-357 (2004).

    2. El-Ajouz, S., Ray, D., Allsopp, R.C., et al. Molecular basis of selective antagonism of the P2X1 receptor for ATP by NF449 and suramin: Contribution of basic amino acids in the cysteine-rich loop. Br. J. Pharmacol. 165(2), 390-400 (2012).

    3. Hechler, B., Magnenat, S., Zighetti, M.L., et al. Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt]. J. Pharmacol. Exp. Ther. 314(1), 232-243 (2005).

    4. Hohenegger, M., Waldhoer, M., Beindl, W., et al. Gsα-selective G protein antagonists. Proc. Natl. Acad. Sci. USA 95(1), 346-351 (1998).